FAQ on Nutriband Inc.'s Aversa Fentanyl Commercial Manufacturing Scale-Up
Summary
What is Aversa Fentanyl?
Aversa Fentanyl is an abuse-deterrent opioid patch developed by Nutriband Inc., incorporating its AVERSA technology to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Why is the scale-up of Aversa Fentanyl’s commercial manufacturing significant?
The scale-up signifies progress towards making Aversa Fentanyl the world’s first abuse-deterrent opioid patch, aiming to combat the opioid crisis with a product that could achieve peak U.S. sales between $80 million and $200 million.
How does Aversa Fentanyl work?
Aversa Fentanyl integrates Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch, designed to prevent the abuse of the drug while maintaining its therapeutic benefits.
Who is involved in the development of Aversa Fentanyl?
Nutriband Inc. is developing Aversa Fentanyl in collaboration with Kindeva, a global CDMO specializing in drug-device combinations, with production taking place at Kindeva’s U.S.-based transdermal facility.
What are the next steps for Aversa Fentanyl?
The next steps include producing clinical supplies and submitting an Investigational New Drug application to begin a human abuse liability study, as part of the process towards commercialization.
Where can I find more information about Nutriband Inc.?
More information about Nutriband Inc. can be found on their website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.
What is the potential market for Aversa Fentanyl?
Nutriband projects Aversa Fentanyl could achieve peak U.S. sales between $80 million and $200 million, with broader global market ambitions supported by its extensive international patent portfolio.
How does Aversa Fentanyl compare to other opioid treatments?
Aversa Fentanyl aims to be the first abuse-deterrent opioid patch, setting it apart from other opioid treatments by incorporating technology specifically designed to prevent abuse and misuse.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 108251